Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• EGFR exon 20 insertion mutations (Ex20ins) and HER2 mutations define a specific subtype of non-small-cell lung cancer (NSCLC).
• This NSCLC subtype is often linked to specific patient demographics and histology, including never/light smokers, females, and adenocarcinoma.
• Despite targeted therapies, treating Ex20ins-mutant and HER2-mutant advanced NSCLC remains challenging due to diagnostic and treatment access issues.

Purpose of the Study:

• To summarize the challenges in diagnosing and treating advanced NSCLC with Ex20ins or HER2 mutations.
• To review current targeted therapies and their limitations for these specific NSCLC subtypes.
• To propose a treatment algorithm for patients with these genetic aberrations.

Main Methods:

• Review of current literature on EGFR exon 20 insertion mutations and HER2 mutations in NSCLC.
• Analysis of diagnostic tools, including next-generation sequencing, for identifying these mutations.
• Evaluation of existing targeted therapies (TKIs, monoclonal antibodies, ADCs) and their clinical utility.

Main Results:

• Identification of Ex20ins and HER2 mutations requires sophisticated diagnostic methods like next-generation sequencing.
• Current targeted drugs (poziotinib, mobocertinib, amivantamab, trastuzumab deruxtecan) show activity but are often used in pretreated patients.
• Access to these targeted therapies can be limited globally.

Conclusions:

• Personalized treatment for Ex20ins-mutant and HER2-mutant advanced NSCLC requires overcoming diagnostic and therapeutic access challenges.
• Development of novel, highly active first-line therapies is crucial for improving patient prognosis.
• A clear treatment algorithm is needed to guide the management of patients with these specific NSCLC genetic alterations.